Novo's denecimig wins EU approval for haemophilia A prophylaxis
Novo has secured European Commission marketing authorisation for FREHEMGO® (denecimig) as routine prophylaxis to prevent or reduce bleeding episodes in adults and children with haemophilia A, with or without inhibitors. The decision, issued on 13 November 2026, follows a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) in September.
Denecimig is a bispecific antibody that mimics the cofactor function of activated Factor VIII, bridging Factor IXa and Factor X to restore thrombin generation. It is administered subcutaneously via a single-use pre-filled pen and is, according to Novo, the first FVIIIa mimetic to offer three dosing intervals within a single approved label: once monthly, once every two weeks, and once weekly. The company said it plans to launch in the first European countries in the coming year, though it has not named specific markets or provided a timeline for broader rollout.
Clinical evidence
The approval rests on data from the FRONTIER clinical programme, a five-study package evaluating denecimig across paediatric and adult populations. The pivotal FRONTIER2 trial demonstrated a statistically significant reduction in annualised bleeding rates versus prior clotting factor prophylaxis and on-demand treatment in patients with or without inhibitors, with results published in the New England Journal of Medicine. FRONTIER3, which assessed children under twelve, showed consistent efficacy with the adolescent and adult data. Across the broader programme, a substantial proportion of participants experienced zero treated bleeds.
FRONTIER5, a direct switch study from emicizumab to denecimig, reported no new safety signals. It also documented a clear patient preference for the denecimig pen device and showed a sustained increase in thrombin generation into the normal range without evidence of a thrombotic risk signal. That last finding is particularly important given the mechanistic concern that any FVIIIa mimetic could, in theory, over-correct coagulation.
Martin Holst Lange, Novo's Chief Scientific Officer and Executive Vice President of Research and Development, said the approval "reflects the strength and consistency of the FRONTIER programme, which showed strong bleed protection across adults and children, with and without inhibitors."
Market context
Haemophilia A prophylaxis is a well-established but commercially competitive space. Roche's emicizumab (Hemlibra), itself a bispecific FVIIIa mimetic, gained EU approval in 2018 and has since become the standard of care for many inhibitor patients, with uptake expanding into the non-inhibitor population. Novo's decision to include a direct head-to-head switch study in the FRONTIER programme, rather than relying purely on comparisons with factor replacement, signals an explicit intent to position denecimig as the next step beyond emicizumab.
The three-interval dosing schedule is a potential differentiator: emicizumab's label offers weekly, fortnightly and four-weekly options, so the competitive advantage for denecimig may rest more on thrombin generation data and device preference than on scheduling novelty alone. Payers and formulary committees across European markets will want to scrutinise relative efficacy and cost-effectiveness before granting unrestricted reimbursement.
Denecimig is already approved in Saudi Arabia and is under active review by the US Food and Drug Administration, as well as other regulatory agencies. A US approval decision, if granted, would significantly expand the addressable market. Novo has not disclosed a PDUFA date or the timing of any FDA advisory committee review. For now, the EU authorisation establishes the product's first major market presence and sets the clinical bar against which subsequent regulatory submissions will be measured.